Publications by authors named "Filip Janku"

Claim this Profile
T
Tumor-agnostic detection of circulating tumor DNA in patients with advanced pancreatic cancer using targeted DNA methylation sequencing and cell-free DNA fragmentomics.
Morten Lapin, Kjersti Tjensvoll, Karin Hestnes Edland, Satu Oltedal, Herish Garresori, Filip Janku

Mol Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131).
Mohamed A Gouda, Filip Janku, Ying Yuan, Leylah M Drusbosky, Alice P Chen

Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors.
Blessie Elizabeth Nelson, Filip Janku, Siqing Fu, Ecaterina E Dumbrava, David S Hong

Clin Cancer Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy, Safety, and Logistics of Preoperative vs Postoperative Stereotactic Radiation Therapy: A Preliminary Analysis of a Randomized Clinical Trial.
Debra Nana Yeboa, Jing Li, Ruitao Lin, Sujit S Prabhu, Thomas H Beckham, Filip Janku

JAMA Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PIK3CB Inhibitor GSK2636771 in Cancers With Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
Filip Janku, Opeyemi A Jegede, Shannon L Puhalla, Panagiotis A Konstantinopoulos, Funda Meric-Bernstam

JCO Precis Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study.
Kyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, Jing Gong, Selma Sulovic, Filip Janku

Invest New Drugs· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 basket study of talabostat, a small-molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers.
Jibran Ahmed, Filip Janku, Daniel D Karp, Sarina A Piha-Paul, Apostolia M Tsimberidou

Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H.
Mohamed A Gouda, Zihan Wei, Jordi Rodon, Michael A Davies, Filip Janku

JCO Precis Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma.
Omar Alhalabi, Mohamed A Gouda, Denái R Milton, Hassan Ahmed Momin, Bulent Yilmaz, Filip Janku

Cancer Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early-Stage Malignant Melanoma.
Jiri Polivka, Mohamed A Gouda, Mahyar Sharif, Martin Pesta, Helen Huang, Filip Janku

Cancer Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors.
Filip Janku, Grace M Choong, Mateusz Opyrchal, Afshin Dowlati, Cinta Hierro

Cancers (Basel)· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.
Vivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, Apostolia M Tsimberidou, Filip Janku

Cancer Res Commun· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.
Filip Janku, Tae Min Kim, Gopakumar Iyer, Anna Spreafico, Elena Elez

Eur J Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery.
Mohamed A Gouda, Filip Janku, Neeta Somaiah, Kelly K Hunt, Sireesha Yedururi

Oncoscience· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ALK fusions in the pan-cancer setting: another tumor-agnostic target?
Aditya Shreenivas, Filip Janku, Mohamed A Gouda, Hui-Zi Chen, Ben George

NPJ Precis Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis.
Ashley Aaroe, Razelle Kurzrock, Gaurav Goyal, Aaron M Goodman, Harsh Patel, Filip Janku

Blood Adv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies.
Jason J Luke, Sarina A Piha-Paul, Theresa Medina, Claire F Verschraegen, Mary Varterasian, Filip Janku

Clin Cancer Res· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors.
Filip Janku, Milind M Javle, Shiraj Sen, Shubham Pant, Lindsay G Bramwell

Cancer· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutation-Agnostic Detection of Colorectal Cancer Using Liquid Biopsy-Based Methylation-Specific Signatures.
Mohamed A Gouda, Dzifa Y Duose, Morten Lapin, Stephanie Zalles, Helen J Huang, Filip Janku

Oncologist· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study.
Blessie Elizabeth Nelson, Jason Roszik, Filip Janku, David S Hong, Shumei Kato

NPJ Precis Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer.
Faye M Johnson, Filip Janku, Mohamed A Gouda, Hai T Tran, Jitesh D Kawedia

Oncologist· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Characterization and Phase I Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies.
Filip Janku, Sae-Won Han, Toshihiko Doi, Alessio Amatu, Jaffer A Ajani

Cancer Immunol Res· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology.
Henry Hiep Vo, Siqing Fu, David S Hong, Daniel D Karp, Sarina Piha-Paul, Filip Janku

NPJ Precis Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial.
Tito R Mendoza, David S Hong, Christine B Peterson, Bettzy Stephen, Ecaterina Dumbrava, Filip Janku

Sci Rep· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Mutations in Circulating Tumor DNA in Patients With Cancer.
Kyaw Z Thein, Amadeo B Biter, Kimberly C Banks, Andrew W Duda, Jennifer Saam, Filip Janku

JCO Precis Oncol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis